MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.eururo.2024.10.024

Медицинская библиотека · European urology · 2024

Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma.

Kim Kwanghee, Alam Syed M, Kuo Fengshen, Chen Ziyu, Yip Wesley, Katims Andrew B, Chu Carissa, Lenis Andrew T, Hu Wenhuo, Gokturk Ozcan Gamze, Chen Jie-Fu, Firouzi Sanaz, Elhanati Yuval, Clinton Timothy N, Aulitzky Andreas, Almassi Nima, Fujii Yoich, Tracey Andrew T, Reisz Peter A, Budhu Sadna, Vuong Lynda, Eichholz Jordan, Woo Hyung Jun, Nogueira Lucas, Gao Sizhi P, Scherz Avigdor, Aggen David H, Rosenberg Jonathan E, Pietzak Eugene J, Seshan Venkatraman, Greenbaum Benjamin, Becker Anton, Akin Oguz, Iyer Gopa, Al-Ahmadie Hikmat, Hakimi A Ari, Merghoub Taha, Solit David B, Coleman Jonathan A

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVE

Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed multi-omic analysis of UTUC tumors to identify molecular features associated with disease recurrence and response to immune checkpoint blockade (ICB).

METHODS

Targeted DNA and whole transcriptome RNA sequencing was performed on 100 UTUC tumors collected from patients undergoing nephroureterectomy. Consensus non-negative matrix factorization was used to identify molecular clusters associated with clinical outcomes. Gene set enrichment and immune deconvolution analyses were performed. Weighted gene co-expression network analysis was employed for unsupervised identification of gene networks in each cluster.

KEY FINDINGS AND LIMITATIONS: Five molecular clusters with distinct clinical outcomes were identified. Favorable subtypes (C1 and C2) were characterized by a luminal-like signature and an immunologically depleted tumor microenvironment (TME). Subtype C3 was characterized by FGFR3 alterations and a higher tumor mutational burden, and included all tumors with microsatellite instability. Despite higher rates of recurrence and inferior survival, subtypes C4 and C5 harbored an immunologically rich TME favoring response to ICB. Limitations include extrapolation of molecular features of tumors from the primary site to determine response to systemic immunotherapy and the limited resolution of bulk sequencing to distinguish gene expression in the tumor, stroma, and immune compartments.

CONCLUSIONS AND CLINICAL IMPLICATIONS: RNA sequencing identified previously underappreciated UTUC molecular heterogeneity and suggests that UTUC patients at the highest risk of metastatic recurrence following surgery include those most likely to benefit from perioperative ICB.

Для цитирования: Kim Kwanghee, Alam Syed M, Kuo Fengshen, Chen Ziyu, Yip Wesley, Katims Andrew B, Chu Carissa, Lenis Andrew T, Hu Wenhuo, Gokturk Ozcan Gamze, Chen Jie-Fu, Firouzi Sanaz, Elhanati Yuval, Clinton Timothy N, Aulitzky Andreas, Almassi Nima, Fujii Yoich, Tracey Andrew T, Reisz Peter A, Budhu Sadna, Vuong Lynda, Eichholz Jordan, Woo Hyung Jun, Nogueira Lucas, Gao Sizhi P, Scherz Avigdor, Aggen David H, Rosenberg Jonathan E, Pietzak Eugene J, Seshan Venkatraman, Greenbaum Benjamin, Becker Anton, Akin Oguz, Iyer Gopa, Al-Ahmadie Hikmat, Hakimi A Ari, Merghoub Taha, Solit David B, Coleman Jonathan A. Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma.. European urology. 2024. DOI: 10.1016/j.eururo.2024.10.024.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.